USC.edu
Are you a Patient?

Hossein Jadvar, MD, PhD

Professor of Radiology

Image of Hossein Jadvar, MD, PhD
Websites
Is this your profile? Click to edit
Phone +1 323 442 1107
Email jadvar@usc.edu
Orcid ID CTSI Profile

Overview

Hossein Jadvar, MD, PhD, MPH, MBA, MSL, FACNM, FSNMMI
Professor of Radiology, Urology, and Biomedical Engineering (Tenured)
University of Southern California, Los Angeles, CA, USA
Past President, American College of Nuclear Medicine (ACNM)
Past President, Society of Nuclear Medicine and Molecular Imaging (SNMMI)
President, SNMMI Therapy Center of Excellence
Chair, U.S. Nuclear Regulatory Commission Advisory Committee on Medical Uses of Isotopes (NRC-ACMUI)
Director, American Board of Nuclear Medicine (ABNM)
Distinguished Investigator, Academy for Radiology and Biomedical Imaging Research

Dr. Jadvar is currently a tenured Professor of Radiology in the Keck School of Medicine (KSOM), at the University of Southern California (USC), Los Angeles, California, USA. He has joint appointments as Professor of Urology, KSOM, and Professor of Biomedical Engineering, USC Viterbi School of Engineering, and is a full member of the USC Norris Comprehensive Cancer Center. He is the past president and fellow of both the American College of Nuclear Medicine (ACNM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). He currently serves as the president of the SNMMI Therapy Center of Excellence.

Dr. Jadvar immigrated to the United States in 1978 after completing his education at Alborz High School in Tehran, Iran. He received the BS degree in chemical engineering from Iowa State University, Ames (1982), MS in biomedical engineering from University of Wisconsin, Madison (1984), MS in computer engineering (1986) and PhD in bioengineering (1988), both from the University of Michigan, Ann Arbor, the MD degree from the University of Chicago Pritzker School of Medicine (1993), Master’s in Public Health (MPH) degree from Harvard University (2005), the Executive Master’s in Business Administration (MBA) from the USC Marshall School of Business (2007, and Master’s in Studies of Law (MSL) from the USC Gould School of Law. He was an intern in internal medicine at the University of California San Francisco (UCSF) during 1993-94, a diagnostic radiology and nuclear medicine resident at Stanford University, during 1994-98, and a clinical fellow in nuclear oncology and positron emission tomography (PET) with the Harvard Medical School Joint Program in Nuclear Medicine, during 1998-99. He has completed executive educational certificate programs in clinical effectiveness at Harvard Medical School, and in leadership at the Wharton School of the University of Pennsylvania. He has also attended summer educational enrichment programs at the University of Oxford, UK, and the University of Cambridge, UK.

He was a Visiting Associate Scientist in Bioengineering at the California Institute of Technology (Caltech) in Pasadena, during 2001-2006. Dr. Jadvar is on the leadership editorial boards of Journal of Nuclear Medicine (Associate Editor), European Journal of Nuclear Medicine and Molecular Imaging (Associate Editor), Radiology (Consultant to the Editor), Theranostics (Associate Editor), and Clinical Nuclear Medicine (Deputy Editor), and is member of the editorial boards of many other peer-reviewed scientific and medical journals. He is the past recipient of the SNMMI Mark Tetalman Young Investigator Award, the Western Regional SNMMI Distinguished Scientist Award and Distinguished Service Award, the Academy for Radiology and Biomedical Imaging Research Distinguished Investigator Award, the inaugural fellowship in the USC Center for Excellence in Research, the inaugural Prof. Ajit Padhy Oration Award from the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), the Prof. RD Lee Oration Award from the Association of Nuclear Physicians of India (ANMPI), the SNMMI PET Center of Excellence Peter Valk Memorial Award, the Best Mentor Awards from both USC and ACNM, the Lifetime Achievement Award from ACNM, and the Distinguished Alumnus Award from Massachusetts General Hospital Department of Radiology, Harvard Medical School.

Dr. Jadvar has been serving since 2019 as the nuclear medicine physician representative on the U.S. Nuclear Regulatory Commission (NRC) Advisory Committee on Medical Uses of Isotopes (ACMUI) and was appointed as the Vice Chair of this Committee in 2022, and as Chair in 2024. He was selected to serve on the Board of Directors of the American Board of Nuclear Medicine (ABNM) in 2023.

He has been a National Institutes of Health (NIH) funded investigator and serves on multiple NIH review panels (with one term as a chartered member for MEDI study section), and the Department of Defense (DOD) Congressionally Directed Medical Research Programs-Prostate Cancer Research Program, the Department of Energy (DOE) Isotope R&D and Production Program, and the Imaging Technology and Informatics Review Panel of the Cancer Prevention Research Institute of Texas (CPRIT). He has written 180 peer-reviewed journal articles, published 4 books, 40 book chapters, 9 U.S. and European patents, numerous conference abstracts and full articles, and has had more than 300 invited lecturer and visiting professorships at national and international venues. His research interests include translational molecular imaging research with particular current interest in prostate cancer, theranostics, and radiopharmaceutical therapy.

As of March 15 2024:
Web of Science: 258 publications, 4705 citations (17.85 average citations per item), h-index 36
Google Scholar: 8362 citations, h-index 50, i10 index 127
ORCID: 0000-0002-9455-2484

BOOKS
1. Jadvar H, Parker JA. Clinical PET and PET/CT. Springer-Verlag, Inc., London, UK. 2005. (ISBN 1 85233-838-5)
2. Jadvar H, Jacene H, Graham M (Eds.). Molecular Imaging: An Introduction. Cambridge University Press, Cambridge, UK. 2017. (ISBN 978-1-107-62128-2)
3. Jadvar H, Colletti PM (Eds.). Nuclear Medicine: The Essentials. Wolter-Kluwer, Inc., Philadelphia, PA. 2022. (ISBN-13: 978-1-4963-00645)
4. Gholamrezanejad A, Assadi M, Jadvar H (Eds.). Radiology-Nuclear Medicine Diagnostic Imaging: A Correlative Approach. John Wiley & Sons Ltd., Hoboken, NJ. 2023. (ISBN 9781119603610)

PATENTS1.
1. Jadvar H, Arzbaecher RC Artifact Suppressing Apparatus and Method. International Patent #WO/1989/009514, May 10, 1989
2. Metzger WT, Jadvar H. Variable Stiffness Esophageal Catheter. U.S. Patent #4,930,521, June 5, 1990.
3. Jadvar H, Metzger WT. Multiple Electrode Affixable Sheet. European Patent #EP381816A2, August 16, 1990
4. Jadvar H, Metzger WT. Multiple Electrode Affixable Sheet. European Patent #EP381816A2, November 7, 1990
5. Jadvar H, Arzbaecher RC. Method and Apparatus for Detection of Posterior Ischemia. U.S. Patent #5,010,888, April 30, 1991.
6. Jadvar H, Metzger WT. Multiple Electrode Affixable Sheet. U.S. Patent #5,069,215, December 3, 1991.
7. Metzger WT, Jadvar H. Variable Stiffness Esophageal Catheter. European Patent #90905336.5, January 21, 1992.
8. Jadvar H, Metzger WT. Multiple Electrode Affixable Sheet. U.S. Patent #5,109,851, May 5, 1992.
9. Metzger WT, Jadvar H. Expandable Esophageal Catheter. U.S. Patent #5,117,828, June 2, 1992.

Awards

  • Massachusetts General Hospital, Harvard Medical School: Distinguished Alumnus Award, 2024
  • Association of Nuclear Physicians of India (ANMPI): Prof. RD Lee Oration Award, 2023
  • American College of Nuclear Medicine (ACNM): Lifetime Achievement Award, 2023
  • University of Southern California: Certificate of Excellence, USC Keck School of Medicine Center for Equity in Medicine and Science, 2021
  • Los Angeles Magazine: Top Doctor (Diagnostic Radiology & Nuclear Medicine), 2020-2023
  • Western Regional Society of Nuclear Medicine: Distinguished Service Award, 2020
  • U.S. Nuclear Regulatory Commission: Advisory Board Member on Medical Uses of Isotopes (Vice Chair 2022-2024, Chair 2024-2028), 2019-2027
  • Society of Nuclear Medicine and Molecular Imaging (SNMMI): Peter E. Valk MD Memorial Award, 2019
  • American College of Nuclear Medicine (ACNM): Best Mentor Award, 2018
  • University of Southern California: Best Mentor Award (Faculty-to-Faculty), 2017
  • Journal of Nuclear Medicine (Supplement on Prostate Cancer): Invited Guest Editor, 2016
  • Society of Nuclear Medicine and Molecular Imaging (SNMMI): Fellow, 2016
  • World Association of Radiopharmacutical and Molecular Therapy (WARMTH): Prof. Ajit Padhy Memorial Oration Award, 2016
  • Academy for Radiology and Biomedical Imaging Research: Distinguished Investigator Award, 2014
  • Best Doctors in America, 2013-2023
  • Pasadena Magazine: San Gabriel Valley Top Doctors, 2010-2023
  • Western Regional Society of Nuclear Medicine: Distinguished Scientist Award, 2010
  • PET Clinics and Theranostics (Prostate Cancer): Invited Guest Editor, 2009
  • Medical Imaging (MEDI) Review Panel, National Institutes of Health (NIH): Charter Member, Medical Imaging Study Section, 2007-2011
  • USC Center for Excellence in Research: Inaugural Faculty Fellow, 2007-2010
  • IEEE-Engineering in Medicine and Biology Society: Senior Member, 2006
  • American College of Nuclear Medicine (ACNM): Fellow, 2003
  • Society of Nuclear Medicine: Marc Tetalman Young Investigator Award, 2000
  • American College of Nuclear Physicians (ACNP): Resident Research Award, 1998
  • Radiological Society of North America: Roentgen Resident/Fellow Research Award, 1997
  • Office of Education, National Institutes of Health (NIH): NIH Resident Research Award, 1994

Publications

  • PSMA PET AUC Updates: Inclusion of rh-PSMA-73. J Nucl Med. 2024 Jan 04. . View in PubMed
  • Sequential and Combination Therapies of 223RaCl2 and Prostate-Specific Membrane Antigen Radioligand Therapy J Nucl Med. 2023 Dec 01; 64(12):1932-1933. . View in PubMed
  • Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy J Nucl Med Technol. 2023 Mar; 51(1):16-21. . View in PubMed
  • A Life Study in Academic Leadership: A Conversation Between Carolyn CMeltzer and Hossein Jadvar. J Nucl Med. 2023 08; 64(8):1167-1170. . View in PubMed
  • Tracking Docetaxel-Induced Cellular Proliferation Changes in Prostate Tumor-Bearing Mice with 18F-FMAU PET Acad Radiol. 2023 08; 30(8):1721-1726. . View in PubMed
  • Integrating Theranostics Into Patient Care Pathways: AJR Expert Panel Narrative Review AJR Am J Roentgenol. 2023 05; 220(5):619-629. . View in PubMed
  • SNMMI/ACR/ASNC/SCMR Joint Credentialing Statement for Cardiac PET/MRI: Endorsed by the American Heart Association J Nucl Med. 2023 01; 64(1):149-152. . View in PubMed
  • Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center J Nucl Med. 2022 Dec; 63(12):1836-1843. . View in PubMed
  • Management Impact of Metachronous Oligometastatic Disease Identified on 18F-Fluciclovine (Axumin™) PET/CT in Biochemically Recurrent Prostate Cancer Mol Imaging Biol. 2022 Dec; 24(6):920-927. . View in PubMed
  • SNMMI/ACR/ASNC/SCMR Joint Credentialing Statement for Cardiac PET/MRI: Endorsed by the American Heart Association Circ Cardiovasc Imaging. 2022 Aug; 15(8):e014576. . View in PubMed
  • Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer PET Clin. 2022 Jul; 17(3):389-397. . View in PubMed
  • Oligometastatic Prostate Cancer: Current Status and Future Challenges J Nucl Med. 2022 11; 63(11):1628-1635. . View in PubMed
  • Prostate-specific Membrane Antigen PET: Standard Imaging in Prostate Cancer Radiology. 2022 09; 304(3):609-610. . View in PubMed
  • The VISION Forward: Recognition and Implication of PSMA-/18F-FDG+ mCRPC J Nucl Med. 2022 06; 63(6):812-815. . View in PubMed
  • Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre Eur J Nucl Med Mol Imaging. 2022 06; 49(7):2300-2309. . View in PubMed
  • Updates to Appropriate Use Criteria for PSMA PET J Nucl Med. 2022 05; 63(5):14N. . View in PubMed
  • Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging J Nucl Med. 2022 01; 63(1):59-68. . View in PubMed
  • SNMMI/ACR/ASNC/SCMR joint credentialing statement for cardiac PET/MRI J Cardiovasc Magn Reson. 2022 07 19; 24(1):43. . View in PubMed
  • Author Correction: Low-count whole-body PET with deep learning in a multicenter and externally validated study NPJ Digit Med. 2021 Sep 14; 4(1):139. . View in PubMed
  • Low-count whole-body PET with deep learning in a multicenter and externally validated study NPJ Digit Med. 2021 Aug 23; 4(1):127. . View in PubMed
  • 18F-FDG PET/CT Monitoring of Response to Programmed Death Protein 1 Blockade in Metastatic Basal Cell Carcinoma Clin Nucl Med. 2021 Aug 01; 46(8):e436-e437. . View in PubMed
  • PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California J Cancer Res Clin Oncol. 2021 Jun; 147(6):1803-1811. . View in PubMed
  • Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors Nucl Med Mol Imaging. 2021 Feb; 55(1):31-37. . View in PubMed
  • Targeted a-therapy in non-prostate malignancies Eur J Nucl Med Mol Imaging. 2021 12; 49(1):47-53. . View in PubMed
  • Competitive Advantage of PSMA Theranostics in Prostate Cancer Radiology. 2021 05; 299(2):261-263. . View in PubMed
  • Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review AJR Am J Roentgenol. 2021 04; 216(4):851-859. . View in PubMed
  • Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences Clin Nucl Med. 2020 Sep; 45(9):668-671. . View in PubMed
  • Targeted a-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies Cancer Biother Radiopharm. 2020 Sep; 35(7):475-484. . View in PubMed
  • Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CT Clin Nucl Med. 2020 Sep; 45(9):727-729. . View in PubMed
  • A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy Can Urol Assoc J. 2020 Apr; 14(4):130-138. . View in PubMed
  • Invited Commentary: Nuclear Theranostics-The Path Forward Radiographics. 2020 10; 40(6):1741-1742. . View in PubMed
  • Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment J Nucl Med. 2020 04; 61(4):552-562. . View in PubMed
  • Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 10, RECIST 1. 1, and PSA response criteria. Theranostics. 2020; 10(7):3254-3262. . View in PubMed
  • Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline J Clin Oncol. 2020 06 10; 38(17):1963-1996. . View in PubMed
  • Preclinical evaluation of a 64Cu-labeled disintegrin for PET imaging of prostate cancer Amino Acids. 2019 Nov; 51(10-12):1569-1575. . View in PubMed
  • Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with 18F-NaF PET/CT Nucl Med Mol Imaging. 2019 Aug; 53(4):247-252. . View in PubMed
  • 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA = 1 ng/mL After Definitive Primary Treatment Clin Nucl Med. 2019 Mar; 44(3):e128-e132. . View in PubMed
  • Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT J Nucl Med. 2019 11; 60(11):1524-1530. . View in PubMed
  • 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial Lancet Oncol. 2019 09; 20(9):1286-1294. . View in PubMed
  • Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers AJR Am J Roentgenol. 2019 08; 213(2):286-299. . View in PubMed
  • Editorial Comment J Urol. 2019 08; 202(2):420-421. . View in PubMed
  • Value proposition of PSMA-targeted a-particle radioligand therapy in metastatic prostate cancer Eur J Nucl Med Mol Imaging. 2019 01; 46(1):8-10. . View in PubMed
  • Management of Primary Osseous Spinal Tumors with PET PET Clin. 2019 Jan; 14(1):91-101. . View in PubMed
  • 18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome Br J Radiol. 2018 Nov; 91(1091):20170948. . View in PubMed
  • PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin PET Clin. 2018 Oct; 13(4):609-621. . View in PubMed
  • Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies PET Clin. 2018 Oct; 13(4):623-634. . View in PubMed
  • Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases Clin Nucl Med. 2018 Jul; 43(7):e226-e231. . View in PubMed
  • Incidental Detection of Meningioma by 18F-FMAU PET/CT in a Patient With Suspected Prostate Cancer Clin Nucl Med. 2018 Jul; 43(7):e245-e246. . View in PubMed
  • Clinical Nononcologic Applications of PET/CT and PET/MRI in Musculoskeletal, Orthopedic, and Rheumatologic Imaging AJR Am J Roentgenol. 2018 Jun; 210(6):W245-W263. . View in PubMed
  • Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology J Nucl Med. 2018 09; 59(9):1338-1339. . View in PubMed
  • Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors Mol Imaging Biol. 2018 08; 20(4):501-509. . View in PubMed
  • Reply: Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know J Nucl Med. 2018 04; 59(4):715-716. . View in PubMed
  • Point: The Existential Threat to Nuclear Medicine J Am Coll Radiol. 2018 03; 15(3 Pt A):384-386. . View in PubMed
  • Radiotheranostics in Cancer Diagnosis and Management Radiology. 2018 02; 286(2):388-400. . View in PubMed
  • PSMA PET: Transformational Change in Prostate Cancer Management? J Nucl Med. 2018 02; 59(2):228-229.. View in PubMed
  • SNMMI Scientific Delegation to Cuba J Nucl Med. 2018 01; 59(1):15N. . View in PubMed
  • The First Theranostic Conference at the American University of Beirut Medical Center J Nucl Med. 2018 01; 59(1):13N. . View in PubMed
  • PSMA Theranostics: Current Status and Future Directions Mol Imaging. 2018 Jan-Dec; 17:1536012118776068. . View in PubMed
  • Non-oncologic Applications of PET/CT and PET/MR in Musculoskeletal, Orthopedic, and Rheumatologic Imaging: General Considerations, Techniques, and Radiopharmaceuticals J Nucl Med Technol. 2017 Nov 10. . View in PubMed
  • Highlights of articles published in annals of nuclear medicine 2016 Eur J Nucl Med Mol Imaging. 2017 Oct; 44(11):1928-1933. . View in PubMed
  • Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment AJR Am J Roentgenol. 2017 Aug; 209(2):277-288. . View in PubMed
  • The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity Diagnostics (Basel). 2017 Jul 20; 7(3). . View in PubMed
  • Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy World J Nucl Med. 2017 Jul-Sep; 16(3):229-236. . View in PubMed
  • Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer Clin Transl Imaging. 2017 Jun; 5(3):199-208. . View in PubMed
  • Science to Practice: Does FDG Differentiate Morphologically Unstable from Stable Atherosclerotic Plaque? Radiology. 2017 Apr; 283(1):1-3.. View in PubMed
  • Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease J Nucl Med. 2017 12; 58(12):2026-2037. . View in PubMed
  • Future cancer research priorities in the USA: a Lancet Oncology Commission Lancet Oncol. 2017 11; 18(11):e653-e706. . View in PubMed
  • ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body J Nucl Med. 2017 07; 58(7):1174-1176. . View in PubMed
  • Effect of Androgen on Normal Biodistribution of [18F]-2′-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice Anticancer Res. 2017 02; 37(2):475-479. . View in PubMed
  • SNMMI Comment on the 2016 Society of Surgical Oncology “Choosing Wisely” Recommendation on the Use of PET/CT in Colorectal Cancer J Nucl Med. 2017 01; 58(1):11-12. . View in PubMed
  • Duplex Doppler sonography: is there clinical relevance to elevated renal vein velocity in kidney transplants? Clin Imaging. 2016 Nov – Dec; 40(6):1237-1245.. View in PubMed
  • Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer J Nucl Med. 2016 Oct; 57(Suppl 3):19S-24S. . View in PubMed
  • PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer J Nucl Med. 2016 Oct; 57(Suppl 3):25S-29S. . View in PubMed
  • Update on advances in molecular PET in urological oncology Jpn J Radiol. 2016 Jul; 34(7):470-85. . View in PubMed
  • SNMMI Leadership Update: Pathways to the Future of Nuclear Medicine J Nucl Med. 2016 Apr; 57(4):15N. . View in PubMed
  • Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med. 2016 11; 46(6):502-506.. View in PubMed
  • Radiotheranostics in Prostate Cancer: Introduction and Overview J Nucl Med. 2016 10; 57(Suppl 3):1S-2S. . View in PubMed
  • Pathways to the Future of Nuclear Medicine Task Force: Phase 1 Report J Nucl Med. 2016 09; 57(9):17N-9N. . View in PubMed
  • Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer Abdom Radiol (NY). 2016 05; 41(5):889-98. . View in PubMed
  • Targeted Radionuclide Therapy: Practical Applications and Future Prospects Biomark Cancer. 2016; 8(Suppl 2):35-8. . View in PubMed
  • SNMMI Leadership Update: Developing Evidence-Based Appropriate Use Criteria under the Protecting Access to Medicare Act of 2014 J Nucl Med. 2015 Nov; 56(11):20N. . View in PubMed
  • Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis Tomography. 2015 Sep; 1(1):18-22. . View in PubMed
  • PSMA PET in Prostate Cancer J Nucl Med. 2015 Aug; 56(8):1131-2. . View in PubMed
  • Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT Clin Nucl Med. 2015 Aug; 40(8):e426-8. . View in PubMed
  • Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy J Nucl Med. 2015 Jul; 56(7):1119-29. . View in PubMed
  • One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer Cancer Biother Radiopharm. 2015 Jun; 30(5):195-9. . View in PubMed
  • American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain J Nucl Med. 2015 Apr; 56(4):642-5. . View in PubMed
  • Prognostic Utility of PET in Prostate Cancer PET Clin. 2015 Apr; 10(2):255-63. . View in PubMed
  • Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases Radiology. 2015 Feb; 274(2):624-5. . View in PubMed
  • Sodium 18F-fluoride PET/CT of bone, joint, and other disorders Semin Nucl Med. 2015 Jan; 45(1):58-65. . View in PubMed
  • Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography Asia Ocean J Nucl Med Biol. 2015; 3(2):72-6. . View in PubMed
  • SNMMI comment on ASCO 2013 “Choosing wisely” recommendation on use of PET/CT in recurrent cancer surveillance J Nucl Med. 2014 May; 55(5):699-700. . View in PubMed
  • The SNMMI and EANM practice guideline for tele-nuclear medicine 20. J Nucl Med Technol. 2014 Mar; 42(1):15-9. . View in PubMed
  • Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature Am J Nucl Med Mol Imaging. 2014; 4(6):580-601. . View in PubMed
  • Competitive advantage of PET/MRI Eur J Radiol. 2014 Jan; 83(1):84-94. . View in PubMed
  • Targeted a-particle therapy of bone metastases in prostate cancer Clin Nucl Med. 2013 Dec; 38(12):966-71. . View in PubMed
  • Molecular imaging of prostate cancer with PET J Nucl Med. 2013 Oct; 54(10):1685-8. . View in PubMed
  • Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer J Nucl Med. 2013 Aug; 54(8):1195-201. . View in PubMed
  • Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations Eur J Nucl Med Mol Imaging. 2013 Jul; 40 Suppl 1:S5-10. . View in PubMed
  • FDG-PET/MRI fusion demonstrating cricoarytenoid muscle hypermetabolism due to contralateral true vocal cord paralysis Rev Esp Med Nucl Imagen Mol. 2012 Nov-Dec; 31(6):362-3. . View in PubMed
  • The SNMMI practice guideline for therapy of thyroid disease with 131I 30. J Nucl Med. 2012 Oct; 53(10):1633-51. . View in PubMed
  • [18F]-2′-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations Mol Imaging. 2012 Sep-Oct; 11(5):426-32. . View in PubMed
  • Molecular imaging of prostate cancer: PET radiotracers AJR Am J Roentgenol. 2012 Aug; 199(2):278-91. . View in PubMed
  • PET/CT in prostate cancer: non-choline radiopharmaceuticals Q J Nucl Med Mol Imaging. 2012 Aug; 56(4):367-74. . View in PubMed
  • Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers Semin Nucl Med. 2012 Jul; 42(4):247-54. . View in PubMed
  • Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer Clin Nucl Med. 2012 Jul; 37(7):637-43. . View in PubMed
  • Multimodality imaging in biochemical recurrence of prostate cancer: utility of (18)F-NaF PET/CT in early detection of metastasis Rev Esp Med Nucl Imagen Mol. 2012 Jul-Aug; 31(4):231-2. . View in PubMed
  • Preservation of retinotopic map in retinal degeneration Exp Eye Res. 2012 May; 98:88-96. . View in PubMed
  • Can Choline PET Tackle the Challenge of Imaging Prostate Cancer? Theranostics. 2012; 2(3):331-2.. View in PubMed
  • FDG PET/CT demonstration of pancreatic metastasis from prostate cancer Clin Nucl Med. 2011 Oct; 36(10):961-2. . View in PubMed
  • Colonic FDG uptake pattern in subjects receiving oral contrast with no known or suspected colonic disease Clin Nucl Med. 2011 Sep; 36(9):754-6. . View in PubMed
  • ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources Clin Nucl Med. 2011 Aug; 36(8):e72-80. . View in PubMed
  • Modeling and percept of transcorneal electrical stimulation in humans IEEE Trans Biomed Eng. 2011 Jul; 58(7):1932-9. . View in PubMed
  • Prostate cancer Methods Mol Biol. 2011; 727:265-90. . View in PubMed
  • Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline J Nucl Med. 2011 Jan; 52(1):81-9. . View in PubMed
  • Evolving cardiac conduction phenotypes in developing zebrafish larvae: implications to drug sensitivity Zebrafish. 2010 Dec; 7(4):325-31. . View in PubMed
  • The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo Prostate. 2010 Sep 01; 70(12):1359-70. . View in PubMed
  • Influence of trigger PSA and PSA kinetics on (11)C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy J Nucl Med. 2010 Mar; 51(3):498-9; author reply 499-500. . View in PubMed
  • 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization J Nucl Med. 2009 Nov; 50(11):1820-7. . View in PubMed
  • Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET Nat Rev Urol. 2009 Jun; 6(6):317-23. . View in PubMed
  • FDG PET in Prostate Cancer PET Clin. 2009 Apr 01; 4(2):155-61. . View in PubMed
  • Role of Imaging in Prostate Cancer PET Clin. 2009 Apr 01; 4(2):135-8. . View in PubMed
  • Preface PET Clin. 2009 Apr; 4(2):ix. . View in PubMed
  • Molecular imaging of prostate cancer: a concise synopsis Mol Imaging. 2009 Mar-Apr; 8(2):56-64. . View in PubMed
  • Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma Hell J Nucl Med. 2009 Jan-Apr; 12(1):26-9. . View in PubMed
  • [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland Ann Nucl Med. 2008 Nov; 22(9):787-93. . View in PubMed
  • Choline autoradiography of human prostate cancer xenograft: effect of castration Mol Imaging. 2008 May-Jun; 7(3):147-52. . View in PubMed
  • A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease Eur J Radiol. 2008 Mar; 65(3):449-61. . View in PubMed
  • [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma Int J Clin Oncol. 2008 Feb; 13(1):42-7. . View in PubMed
  • PET and PET/CT in pediatric oncology Semin Nucl Med. 2007 Sep; 37(5):316-31. . View in PubMed
  • [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma J Comput Assist Tomogr. 2007 Mar-Apr; 31(2):223-8. . View in PubMed
  • Adenocarcinoma in an Indiana pouch on PET-CT Clin Nucl Med. 2007 Jan; 32(1):57-8. . View in PubMed
  • Actinomycosis mimicking anastomotic recurrent esophageal cancer on PET-CT Clin Nucl Med. 2006 Oct; 31(10):646-7. . View in PubMed
  • 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer Mol Imaging Biol. 2006 May-Jun; 8(3):193-200. . View in PubMed
  • FDG PET-CT demonstration of Sjogren’s sialoadenitis Clin Nucl Med. 2005 Oct; 30(10):698-9. . View in PubMed
  • Glucose metabolism of human prostate cancer mouse xenografts Mol Imaging. 2005 Apr-Jun; 4(2):91-7. . View in PubMed
  • PET in pediatric diseases Radiol Clin North Am. 2005 Jan; 43(1):135-52. . View in PubMed
  • The reproductive tract Semin Nucl Med. 2004 Oct; 34(4):262-73. . View in PubMed
  • Musculoskeletal system Semin Nucl Med. 2004 Oct; 34(4):254-61. . View in PubMed
  • Electrocardiographic characterization of embryonic zebrafish Conf Proc IEEE Eng Med Biol Soc. 2004; 2004:3615-7. . View in PubMed
  • Fusion positron emission tomography-computed tomography demonstration of epidural metastases Clin Nucl Med. 2004 Jan; 29(1):39-40. . View in PubMed
  • Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma Clin Nephrol. 2003 Dec; 60(6):395-400. . View in PubMed
  • FDG PET in suspected recurrent and metastatic prostate cancer Oncol Rep. 2003 Sep-Oct; 10(5):1485-8. . View in PubMed
  • Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography Clin Radiol. 2003 Mar; 58(3):215-21. . View in PubMed
  • Diagnostic utility of FDG PET in multiple myeloma Skeletal Radiol. 2002 Dec; 31(12):690-4. . View in PubMed
  • Pharmacologic interventions in nuclear radiology: indications, imaging protocols, and clinical results Radiographics. 2002 May-Jun; 22(3):477-90. . View in PubMed
  • Evaluation of pancreatic carcinoma with FDG PET Abdom Imaging. 2001 May-Jun; 26(3):254-9. . View in PubMed
  • Non-visualization of sentinel lymph node in patients with breast cancer Nucl Med Commun. 2001 Jan; 22(1):25-32. . View in PubMed
  • Comparison of fluorine-18 deoxyglucose and O-15 water PET in temporal lobe epilepsy Acta Neurol Belg. 2000 Dec; 100(4):214-20. . View in PubMed
  • Medical imaging in microgravity Aviat Space Environ Med. 2000 Jun; 71(6):640-6. . View in PubMed
  • The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma Clin Nucl Med. 2000 Jan; 25(1):48-51. . View in PubMed
  • Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose Clin Nucl Med. 1999 Dec; 24(12):965-7. . View in PubMed
  • Physiologic Source of Intestinal FDG UptakeEffect of Atropine and Sincalide. Clin Positron Imaging. 1999 Nov; 2(6):318. . View in PubMed
  • SPECT and PET in the evaluation of coronary artery disease Radiographics. 1999 Jul-Aug; 19(4):915-26. . View in PubMed
  • Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography Clin Positron Imaging. 1999 May; 2(3):153-158. . View in PubMed
  • Annular pancreas in adults: imaging features in seven patients Abdom Imaging. 1999 Mar-Apr; 24(2):174-7. . View in PubMed
  • Role of FDG PET in the Evaluation of Rare Tumors Clin Positron Imaging. 1998 Sep; 1(4):239. . View in PubMed
  • Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography Nucl Med Commun. 1998 Jun; 19(6):547-54. . View in PubMed
  • Effect of radionuclide renograms on treatment of patients with spinal cord injuries AJR Am J Roentgenol. 1997 Oct; 169(4):1045-7. . View in PubMed
  • False-negative fluorine-18-FDG PET in metastatic carcinoid J Nucl Med. 1997 Sep; 38(9):1382-3. . View in PubMed
  • Still the great mimicker: abdominal tuberculosis AJR Am J Roentgenol. 1997 Jun; 168(6):1455-60. . View in PubMed
  • Computer analysis of the electrocardiogram during esophageal pacing cardiac stress IEEE Trans Biomed Eng. 1991 Nov; 38(11):1089-99. . View in PubMed
  • A reusable perfusion supporting tissue-mimicking material for ultrasound hyperthermia phantoms Med Phys. 1990 May-Jun; 17(3):380-90. . View in PubMed
  • Utility of a stimulus artifact suppressor for transesophageal pacing Am J Cardiol. 1990 Feb 01; 65(5):393-4. . View in PubMed
  • A system for simultaneous esophageal atrial pacing and ventricular recording in computer analysis of posterior ischemia J Electrocardiol. 1989; 22 Suppl:248-52. . View in PubMed
  • The pill electrodeNew technology as an adjunct to nursing assessment of patient arrhythmias. Prog Cardiovasc Nurs. 1989 Jan-Mar; 4(1):10-7. . View in PubMed
  • Computer processing of the electrocardiogram during transesophageal atrial pacing-induced stress J Electrocardiol. 1987 Oct; 20 Suppl:106-7. . View in PubMed
  • Lead configurations in esophageal electrocardiography Med Instrum. 1987 Jun; 21(3):158-65. . View in PubMed

Similar People